• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Molecules, Vol. 28, Pages 2400: Bruton & rsquo;s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
Molecules, Vol. 28, Pages 2400: Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials Molecules doi: 10.3390/molecules28052400 Authors: Dariusz Rozkiewicz Justyna Magdalena Hermanowicz Iwona Kwiatkowska Anna Krupa Dariusz Pawlak In the last few decades, there has been a growing interest in Bruton’s tyrosine kinase (BTK) and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) signaling pathway and affects B-cell proliferation and differentiation. Evidence demonstrating the expression of BTK on t...
Source: Molecules - March 6, 2023 Category: Chemistry Authors: Dariusz Rozkiewicz Justyna Magdalena Hermanowicz Iwona Kwiatkowska Anna Krupa Dariusz Pawlak Tags: Review Source Type: research

Eosinophils in cancer: favourable or unfavourable?
Abstract Eosinophils are granulocytic leukocytes residing in blood and tissues in the lung, breast, gastrointestinal and reproductive systems. Eosinophilia is uncommon in healthy individuals, however, it is associated with allergies, helminth infections and some inflammatory states. Eosinophilia has also been observed in cancer, including colorectal, breast, ovarian, cervical, oral squamous, Hodgkin's lymphoma and prostate cancer. Whether an increase in eosinophils leads to a favourable or unfavourable prognosis still remains controversial and depends on many factors including the type of cancer. Eosinophil infilt...
Source: Current Medicinal Chemistry - January 18, 2016 Category: Chemistry Authors: Sakkal S, Miller S, Apostolopoulos V, Nurgali K Tags: Curr Med Chem Source Type: research